Linked Life Data

17065592

Source:http://linkedlifedata.com/resource/pubmed/id/17065592

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-12-27
pubmed:abstractText
Telithromycin, a new ketolide antibiotic, has been implicated in the exacerbation or unmasking of myasthenia gravis. This retrospective study presents two clinical reports and summarizes eight other suspected cases notified to the French pharmacovigilance system, highlighting a potentially life-threatening risk of telithromycin treatment in myasthenic patients. An important common feature was that, in seven cases, symptomatology occurred within 2 hours of first telithromycin intake--notably in cases of severe exacerbation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1526-632X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
26
pubmed:volume
67
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2256-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment.
pubmed:affiliation
Department of Neurology A, Hôpital Neurologique, Hospices Civils de Lyon, France. xavier.perrot@chu-lyon.fr
pubmed:publicationType
Journal Article, Case Reports